Lisata Therapeutics Inc (LSTA)

[Pyrrhonian]

To add to this, there is one additional possibility.

Of course any "outsider" who can trade securities at will and is not subject to the restrictions on "insiders," having been given Ph II results can take up a short or long position accordingly. This would constitute an illegal practice, especially in return for financing.

The most logical conclusion is that NBS does not yet have data but is fully expecting it before the mid Nov conference. Or they have the data and are working through a partnership deal as preferential treatment to some entity (BAX?), as this is not stock exploitation given that those are other insiders whose market actions are likewise strictly monitored (similar to negotiations for buyout). Knowing data and the likelihood of imminent partnering once negotiations have finalized, they may have entered said financing agreement willing to "give away the farm," as to them there was no real risk, understanding the effectiveness of AMR-001 and the high likelihood of partnering this program with BAX or another big pharma. Jmo